Evidence map›Paper›PMID 30546947›Full record

ArticleOncoimmunology

Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials.

Jonathan G Pol, Sergio A Acuna, Beta Yadollahi, Nan Tang, Kyle B Stephenson, Matthew J Atherton, David Hanwell, Alexander El-Warrak, Alyssa Goldstein, Badru Moloo and 17 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 85 citations in OpenAlex.

  1. Review
  2. Review
  3. Oncolytic viruses: advanced strategies in cancer therapy.Signal transduction and targeted therapy · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. VSVNature communications · 2024
    Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Personalizing Oncolytic Immunovirotherapy Approaches.Molecular diagnosis & therapy · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 2 countries.

Jonathan G PolMcMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-8355-7562
Sergio A AcunaToronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-6266-2136
Beta YadollahiChildren's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada.
Nan TangToronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.
Kyle B StephensonTurnstone Biologics, Ottawa, ON, Canada.
Matthew J AthertonMcMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.
David HanwellAnimal Resources Centre, University Health Network, Toronto, ON, Canada.
Alexander El-WarrakAnimal Resources Centre, University Health Network, Toronto, ON, Canada.
Alyssa GoldsteinAnimal Resources Centre, University Health Network, Toronto, ON, Canada.
Badru MolooAnimal Resources Centre, University Health Network, Toronto, ON, Canada.
Patricia V TurnerDepartment of Pathobiology, University of Guelph, Guelph, ON, Canada.
Roberto LopezAnimal Resources Centre, University Health Network, Toronto, ON, Canada.
Sandra LaFranceToronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.
Carole EveleghMcMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.
Galina DenisovaMcMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.
Robin ParsonsMcMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.
Jamie MillarMcMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.
Gautier StollUniversité Paris Descartes, Sorbonne Paris Cité, Paris, France.
Chantal G MartinTurnstone Biologics, Ottawa, ON, Canada.
Julia PomoranskyTurnstone Biologics, Ottawa, ON, Canada.
Caroline J BreitbachTurnstone Biologics, Ottawa, ON, Canada.
Jonathan L BramsonMcMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.ORCID 0000-0003-2874-6886
John C BellTurnstone Biologics, Ottawa, ON, Canada.
Yonghong WanMcMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.
David F StojdlChildren's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada.
Brian D LichtyMcMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.ORCID 0000-0003-4514-1037
J Andrea McCartToronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.
McMaster University · CAUniversity Health Network · CAChildren's Hospital of Eastern Ontario · CADélégation Paris 5 · FRMount Sinai Hospital · CAUniversity of Guelph · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple immunotherapeutics have been approved for cancer patients, however advanced solid tumors are frequently refractory to treatment. We evaluated the safety and immunogenicity of a vaccination approach with multimodal oncolytic potential in non-human primates (NHP) (

Indexed as

Cancer immunotherapyendogenous immunityMAGE-A3MG1 MarabaOncolytic vaccination

Identifiers

PMID30546947
PMCPMC6287790
OpenAlexW2892370845

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.